Vaccinex Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-20.25	-19.82	-22.38	-28.85	-31.86	-29.52	-21.93	-26.23
Depreciation & Amortization	0.12	0.21	0.17	0.31	0.25	0.22	0.21	0.18
Share-Based Compensation	0.47	0.55	0.54	0.73	0.45	0.18	0.32	0.14
Other Operating Activities	2.42	-0.01	-3.63	-0.84	0.45	3.84	-3.19	-6.09
Operating Cash Flow	-17.23	-19.07	-25.3	-28.65	-30.72	-25.28	-21.39	-19.72
Capital Expenditures	-0.07	-0.1	-0.03	-0.29	-0.08	-0.24	-0.07	-0.79
Change in Investments	0	0	0	0	14.15	-14.01	0	0
Investing Cash Flow	-0.07	-0.1	-0.03	-0.29	14.07	-14.24	-0.07	-0.79
Share Issuance / Repurchase	12.52	17.05	31.86	27.78	13.8	46.46	12.02	0
Debt Issued / Paid	-0.07	-0.08	-8.54	8.98	0	-5.5	3.98	5.68
Other Financing Activities	-	-	-	-	-	-	7.98	10.68
Financing Cash Flow	12.45	16.98	23.32	36.76	13.8	40.96	23.97	16.36
Net Cash Flow	-4.86	-2.2	-2.01	7.82	-2.84	1.44	2.52	-4.16
Free Cash Flow	-17.3	-19.17	-25.33	-28.94	-30.79	-25.51	-21.46	-20.51
Free Cash Flow Margin	-3035.26%	-6972.00%	-2814.44%	-4629.92%	-5887.76%	-3523.62%	-23838.89%	-6491.46%
Free Cash Flow Per Share	-37.31	-94.88	-184.38	-323.46	-502.03	-1025.59	-4088.76	-4149.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).